October 15, 2008 - Advanced Circulatory Systems Inc. announced this week it has received an additional $1.5 million in funding from the National Institutes of Health (NIH) to continue a study testing two devices used in combination on those who experience cardiac arrest outside a hospital, where the national average for survival is only one in 20.
The NIH funding will be used to increase enrollment in the six-site study that involves the testing of Advanced Circulatory Systems’ ResQPump, an active compression/decompression device, in combination with the ResQPOD, a device used to increase blood flow to the heart and brain during CPR. The ResQPOD, an impedance threshold device proven to increase circulation, is FDA cleared and currently in use in the U.S.
The current NIH-funded study is the first randomized study in the nation to assess results of the ResQPump and ResQPOD used together and comparing results when CPR is performed without these devices.
The six sites involved in the study include Minneapolis, MN; St. Paul, MN; Whatcom County, WA; Oshkosh, WI; suburban Detroit including parts of Oakland and Macomb counties, MI; and Livingston County, MI which includes the city of Ann Arbor.
The use of new technologies as well as improved CPR procedures as recommended by the American Heart Association's latest guidelines are intended to help more people survive a cardiac arrest and with their brain function intact. Studies like the NIH-funded study are believed to be among the best methods to prove how treatments can impact outcomes.
The generally cleared indication for the ResQPOD is a temporary increase in blood circulation during emergency care, hospital, clinic and home use. Studies are ongoing in the U.S, to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest, hypotension during dialysis and severe blood loss.
For more information: www.advancedcirculatory.com